Long-Term Follow-Up of HLA-A2+ Patients with High-Risk, Hormone-Sensitive Prostate Cancer Vaccinated with the Prostate Specific Antigen Peptide Homologue (PSA146-154)
2010

Long-Term Follow-Up of Prostate Cancer Patients Vaccinated with PSA146-154 Peptide

Sample size: 28 publication 10 minutes Evidence: moderate

Author Information

Author(s): Perambakam Supriya, Xie Hui, Edassery Seby, Peace David J.

Primary Institution: University of Illinois at Chicago

Hypothesis

The study investigates the long-term clinical outcomes and immune responses in HLA-A2+ patients with high-risk, hormone-sensitive prostate cancer vaccinated with the PSA146-154 peptide.

Conclusion

The study found that 50% of patients developed strong immune responses, and those with augmented responses had a decreased risk of biochemical progression.

Supporting Evidence

  • Fifty percent of patients developed strong immune responses to the vaccine.
  • Patients with augmented immune responses had a decreased risk of biochemical progression.
  • The mean overall survival was 60 months for all patients.
  • 14 of 28 patients demonstrated specific release of IFN-γ by week 52.
  • Patients who developed strong T-cell immunity showed a trend towards greater overall survival.

Takeaway

Doctors gave a special vaccine to men with prostate cancer to help their bodies fight the disease, and many of them showed good signs that the vaccine worked.

Methodology

Patients were vaccinated with PSA146-154 peptide and monitored for immune responses and clinical outcomes over several years.

Potential Biases

Potential biases may arise from the lack of a control group and the observational nature of the study.

Limitations

The study had a small sample size and was observational, which may limit the generalizability of the findings.

Participant Demographics

All participants were HLA-A2+ men with high-risk, hormone-sensitive prostate cancer.

Statistical Information

P-Value

0.02

Confidence Interval

95% CI, 51 to 68 months

Statistical Significance

p = 0.02

Digital Object Identifier (DOI)

10.1155/2010/473453

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication